Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-10-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
第六届董事会第三十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 33rd meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It includes information about meeting attendance, voting results on various proposals related to stock incentive plans, share repurchases, capital reduction, and authorization for further actions. The document does not contain financial statements or detailed financial performance data but focuses on board decisions and governance matters. It also references other announcements for detailed content but itself is a formal board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is under 5,000 characters and is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2024-10-28 Chinese
关于召开2024年第三次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2024 third extraordinary general meeting of shareholders (临时股东大会) for Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed, registration methods, and other procedural information. There is no financial data, earnings information, or detailed report content. The document is an announcement about a shareholders meeting rather than the meeting materials or results themselves. It is also not a proxy solicitation or voting results announcement. Given the content and length (2420 characters), it fits the category of a regulatory announcement about a shareholders meeting, which aligns best with Regulatory Filings (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-10-28 Chinese
关于2023年股权激励计划首次授予限制性股票第一个解除限售期解除限售条件及首次授予股票期权第一个行权期行权条件成就的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the achievement of conditions for the first unlocking period of restricted stock and the first exercise period of stock options under the 2023 equity incentive plan. It includes extensive information about the decision-making process, performance targets, individual and company-level assessments, stock option exercise details, and legal opinions. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is a regulatory announcement about equity incentive plan progress and related corporate governance matters. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance and disclosure announcement related to equity incentive plans and stock option exercises, not a financial report or a meeting presentation.
2024-10-28 Chinese
第七届监事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 7th Supervisory Board of Beijing Xinghao Pharmaceutical Co., Ltd. It details meeting attendance, agenda items, voting results, and references to other announcements on the stock exchange platform. The content focuses on internal supervisory board decisions and meeting resolutions rather than financial results, audit opinions, or shareholder voting outcomes. It does not contain financial statements or detailed financial analysis. It is not a report itself but an official meeting resolution announcement. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short (1391 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2024-10-28 Chinese
国浩律师（上海）事务所关于北京星昊医药股份有限公司2023年股权激励计划首次授予限制性股票第一个解除限售期解除限售条件成就、首次授予股票期权第一个行权期行权条件成就及回购注销部分限制性股票、注销部分股票期权相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 equity incentive plan of Beijing Xinghao Pharmaceutical Co., Ltd. It discusses the conditions for the first release of restricted stock, the first exercise period of stock options, repurchase and cancellation of some restricted stocks and stock options, and related approvals and authorizations. The document references various board and supervisory meetings, shareholder meetings, and regulatory compliance related to the equity incentive plan. It is a detailed legal opinion on specific corporate actions related to stock incentives, not a financial report, earnings release, or general regulatory filing. It is not a proxy solicitation, voting results announcement, or remuneration report. The document is a specialized legal opinion on equity incentive plan matters, which does not fit into categories like Annual Report, Interim Report, or Capital Update. The closest fitting category is Regulatory Filings (RNS) as it is a regulatory compliance document related to corporate governance and legal matters but not a direct governance structure report or management change announcement. Therefore, the best classification is Regulatory Filings (RNS).
2024-10-28 Chinese
监事会关于2023年股权激励计划首次授予限制性股票第一个解除限售期解除限售条件、首次授予股票期权第一个行权期行权条件成就及回购注销部分限制性股票、注销部分股票期权的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board opinion on the 2023 equity incentive plan of Beijing Xinghao Pharmaceutical Co., Ltd. It discusses the conditions for lifting restrictions on restricted stocks, exercising stock options, and the repurchase and cancellation of some restricted stocks and stock options. The document references regulatory guidelines related to equity incentive plans and confirms compliance and legality of these actions. It is not a financial report, earnings release, or management discussion, but rather a formal supervisory opinion on equity incentive plan implementation and related share transactions. This fits best under the category of Transaction in Own Shares (POS), as it involves repurchase and cancellation of company shares related to the equity incentive plan. The document length is short and focused on these transactions, not a broader report or announcement of a report publication.
2024-10-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.